Cellectar Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $13.70M
- P/E (TTM)
- –
- Dividend yield
- –
About Cellectar Biosciences
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical firm that develops targeted cancer therapies using a proprietary phospholipid ether drug conjugate platform. Its research pipeline centers on phospholipid radioconjugates that deliver radioactive isotopes directly into malignant cells while sparing healthy tissue. Key product candidates include iopofosine I 131, a beta-emitting agent evaluated for blood cancers, alongside preclinical and early clinical programs CLR 125 and CLR 225, which utilize Auger and alpha radiation for solid tumors. The firm primarily serves cancer patients, targeting adult and pediatric populations diagnosed with conditions such as Waldenstrom macroglobulinemia, multiple myeloma, central nervous system lymphoma, and rare solid tumors.
The company operates clinical development activities across multiple regions, conducting studies in the United States and at international research facilities. Its clinical footprint includes trials administered through approximately ten American cancer centers and seven international pediatric institutions. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Cellectar Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cellectar Biosciences, Inc.
- Headquarters
- Florham Park, NJ
- Address
- 100 Campus Drive 07932
- Phone
- (608) 441-8120
- Website
- cellectar.com
- Employees
- 11, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- CLRB
- Exchange
- Nasdaq
- Shares outstanding
- 9M, Aug 11, 2026
- Public float
- $12.85M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Jun 24, 2025; 1-for-30 reverse, Jun 24, 2025; 1-for-10 reverse, Jul 22, 2022; 1-for-10 reverse, Jun 27, 2022; 1-for-10 reverse, Aug 10, 2018; 1-for-10 reverse, Jul 17, 2018; 1-for-10 reverse, Mar 11, 2016; 1-for-10 reverse, Mar 7, 2016; 1-for-20 reverse, Aug 4, 2014; 1-for-20 reverse, Jun 16, 2014; 1-for-153 reverse, Apr 11, 2011
- SEC CIK
- 1279704
- CUSIP
- 15117F880
- ISIN
- US15117F8804
- LEI
- 5493000NFZCRG7BYQV93
- EIN
- 04-3321804
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James V. Caruso | President & CEO, Director | 20,318 |
| Jarrod Longcor | Chief Operating Officer | 20,451 |
| Chad J. Kolean | CFO | 6,418 |
| John Neis | Director | 10 |
| Asher Chanan-Khan | Director | – |
| Andrew Gu | Director | – |
| Frederick W. Driscoll | Director | 19,417 |
| Douglas J. Swirsky | Director | 25,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 James V. Caruso | $1.06M | $886.57K | $693.68K | $6 | – |
| FY2024 James V. Caruso | $3.04M | $1.32M | $1.53M | $18 | – |
| FY2023 James V. Caruso | $1.97M | $2.35M | $1.24M | $162 | – |
| FY2022 James V. Caruso | $1.46M | $146.85K | $514.62K | $8 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eleven employees, all of whom were full-time.”
Corporate history
Events identified from SEC filings